Literature DB >> 29390132

A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.

Maya Beganovic1,2, Megan K Luther1,2,3, Louis B Rice4,5, Cesar A Arias6,7,8, Michael J Rybak9,10,11, Kerry L LaPlante1,2,3,5.   

Abstract

Enterococci, one of the most common causes of hospital-associated infections, are responsible for substantial morbidity and mortality. Enterococcus faecalis, the more common and virulent species, causes serious high-inoculum infections, namely infective endocarditis, that are associated with cardiac surgery and mortality rates that remained unchanged for the last 30 years. The best cures for these infections are observed with combination antibiotic therapy; however, optimal treatment has not been fully elucidated. It is the purpose of this review to highlight treatment options and their limitations, and provide direction for future investigative efforts to aid in the treatment of these severe infections. While ampicillin plus ceftriaxone has emerged as a preferred treatment option, mortality rates continue to be high, and from a safety standpoint, ceftriaxone, unlike other cephalosporins, promotes colonization with vancomycin resistant-enterococci due to high biliary concentrations. More research is needed to improve patient outcomes from this high-mortality disease.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29390132      PMCID: PMC6248357          DOI: 10.1093/cid/ciy064

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  41 in total

1.  Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage.

Authors:  James A McKinnell; Danielle F Kunz; Eric Chamot; Mukesh Patel; Rhett M Shirley; Stephen A Moser; John W Baddley; Peter G Pappas; Loren G Miller
Journal:  Infect Control Hosp Epidemiol       Date:  2012-05-14       Impact factor: 3.254

2.  In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model.

Authors:  L B Rice; C T Eliopoulos; J D Yao; G M Eliopoulos; R C Moellering
Journal:  Diagn Microbiol Infect Dis       Date:  1992-02       Impact factor: 2.803

3.  A new era for treating Enterococcus faecalis endocarditis: ampicillin plus short-course gentamicin or ampicillin plus ceftriaxone: that is the question!

Authors:  Jose M Miro; Juan M Pericas; Ana del Rio
Journal:  Circulation       Date:  2013-03-29       Impact factor: 29.690

4.  Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.

Authors:  Ashley D Hall; Molly E Steed; Cesar A Arias; Barbara E Murray; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

5.  Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Ann F Bolger; Matthew E Levison; Patricia Ferrieri; Michael A Gerber; Lloyd Y Tani; Michael H Gewitz; David C Tong; James M Steckelberg; Robert S Baltimore; Stanford T Shulman; Jane C Burns; Donald A Falace; Jane W Newburger; Thomas J Pallasch; Masato Takahashi; Kathryn A Taubert
Journal:  Circulation       Date:  2005-06-14       Impact factor: 29.690

Review 6.  Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Imad M Tleyjeh; Michael J Rybak; Bruno Barsic; Peter B Lockhart; Michael H Gewitz; Matthew E Levison; Ann F Bolger; James M Steckelberg; Robert S Baltimore; Anne M Fink; Patrick O'Gara; Kathryn A Taubert
Journal:  Circulation       Date:  2015-09-15       Impact factor: 29.690

7.  Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone.

Authors:  Joan Gavaldà; Oscar Len; José M Miró; Patricia Muñoz; Miguel Montejo; Aristides Alarcón; Julián de la Torre-Cisneros; Carmen Peña; Xavier Martínez-Lacasa; Cristina Sarria; Germán Bou; José M Aguado; Enrique Navas; Joan Romeu; Francesc Marco; Carmen Torres; Pilar Tornos; Ana Planes; Vicenç Falcó; Benito Almirante; Albert Pahissa
Journal:  Ann Intern Med       Date:  2007-04-17       Impact factor: 25.391

8.  β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.

Authors:  Jordan R Smith; Katie E Barber; Animesh Raut; Mostafa Aboutaleb; George Sakoulas; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2015-02-01       Impact factor: 5.790

9.  Role of class A penicillin-binding proteins in PBP5-mediated beta-lactam resistance in Enterococcus faecalis.

Authors:  Ana Arbeloa; Heidi Segal; Jean-Emmanuel Hugonnet; Nathalie Josseaume; Lionnel Dubost; Jean-Paul Brouard; Laurent Gutmann; Dominique Mengin-Lecreulx; Michel Arthur
Journal:  J Bacteriol       Date:  2004-03       Impact factor: 3.490

10.  High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis.

Authors:  Manuela Carugati; Arnold S Bayer; Josè M Miró; Lawrence P Park; Armenio C Guimarães; Athanasios Skoutelis; Claudio Q Fortes; Emanuele Durante-Mangoni; Margaret M Hannan; Francisco Nacinovich; Nuria Fernández-Hidalgo; Paolo Grossi; Ru-San Tan; Thomas Holland; Vance G Fowler; Ralph G Corey; Vivian H Chu
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

View more
  42 in total

1.  Reply to Koehler et al.

Authors:  Maya Beganovic; Megan K Luther; Louis B Rice; Cesar A Arias; Michael J Rybak; Kerry L LaPlante
Journal:  Clin Infect Dis       Date:  2019-08-16       Impact factor: 9.079

2.  Lytic bacteriophages facilitate antibiotic sensitization of Enterococcus faecium.

Authors:  Gregory S Canfield; Anushila Chatterjee; Juliel Espinosa; Mihnea R Mangalea; Emma K Sheriff; Micah Keidan; Sara W McBride; Bruce D McCollister; Howard C Hang; Breck A Duerkop
Journal:  Antimicrob Agents Chemother       Date:  2021-03-01       Impact factor: 5.191

3.  Outcomes of Patients with Bloodstream Infections Caused by Ampicillin-Susceptible but Penicillin-Resistant Enterococcus faecalis: Caution in Interpreting the Results.

Authors:  Nicolo L Cabrera; Alexandre E Malek; Samuel L Aitken; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

4.  Understanding resistance in enterococcal infections.

Authors:  Jordi Rello; Laura Campogiani; Vandana Kalwaje Eshwara
Journal:  Intensive Care Med       Date:  2019-12-02       Impact factor: 17.440

5.  A comparison of different antibiotic regimens for the treatment of infective endocarditis.

Authors:  Arturo J Martí-Carvajal; Mark Dayer; Lucieni O Conterno; Alejandro G Gonzalez Garay; Cristina Elena Martí-Amarista
Journal:  Cochrane Database Syst Rev       Date:  2020-05-14

Review 6.  Resistance in Vancomycin-Resistant Enterococci.

Authors:  William R Miller; Barbara E Murray; Louis B Rice; Cesar A Arias
Journal:  Infect Dis Clin North Am       Date:  2020-12       Impact factor: 5.982

7.  Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.

Authors:  Yuanyuan Jiao; Bartolome Moya; Mong-Jen Chen; Alexandre P Zavascki; Hsinyin Tsai; Xun Tao; Dhruvitkumar S Sutaria; Arnold Louie; John D Boyce; Deanna Deveson Lucas; Tae Hwan Kim; Brian T Tsuji; Robert A Bonomo; George L Drusano; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

8.  High-Level Antibiotic Tolerance of a Clinically Isolated Enterococcus faecalis Strain.

Authors:  Huan Gu; Sweta Roy; Xiaohui Zheng; Tian Gao; Huilin Ma; Zafer Soultan; Christopher Fortner; Shikha Nangia; Dacheng Ren
Journal:  Appl Environ Microbiol       Date:  2020-12-17       Impact factor: 4.792

9.  Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?

Authors:  Laura Herrera-Hidalgo; Arístides de Alarcón; Luis Eduardo López-Cortes; Rafael Luque-Márquez; Luis Fernando López-Cortes; Alicia Gutiérrez-Valencia; María Victoria Gil-Navarro
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

10.  Bacteriophage-Antibiotic Combinations for Enterococcus faecium with Varying Bacteriophage and Daptomycin Susceptibilities.

Authors:  Taylor Morrisette; Katherine L Lev; Razieh Kebriaei; Jacinda C Abdul-Mutakabbir; Kyle C Stamper; Sandra Morales; Susan M Lehman; Gregory S Canfield; Breck A Duerkop; Cesar A Arias; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.